Aligos Therapeutics, Inc. (ALGS) vs Cel-Sci Corporation (CVM)

Aligos Therapeutics, Inc. and Cel-Sci Corporation are both Biotechnology companies. Aligos Therapeutics, Inc. and Cel-Sci Corporation are of similar size ($32.6M and $30.3M). Aligos Therapeutics, Inc. grew revenue faster over the last twelve months: 893.0% against 20.8%. Cel-Sci Corporation has the higher net margin (0.00% vs −241.0%) and the higher return on invested capital (−169.6% vs −3,379.3%). Across the 17 metrics below, Aligos Therapeutics, Inc. leads on 10 and Cel-Sci Corporation on 7.

Valuation

Metric ALGS CVM Biotechnology median
P/E n/m n/m 7.88
P/S 1.82 36.22 11.47
P/B 1.80 1.85 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 0.86 34.83 10.73
Earnings yield (132.49%) (68.40%) (28.84%)
Free cash flow yield (164.46%) (83.02%) (23.03%)

Profitability

Metric ALGS CVM Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (250.63%) 0.00% 0.00%
Net margin (241.01%) 0.00% 0.00%
Free cash flow margin (299.90%) 0.00% 0.00%
Return on equity (113.59%) (252.53%) (57.72%)
Return on assets (75.57%) (108.91%) (49.22%)
Return on invested capital (3,379.28%) (169.59%) 0.00%

Growth

Metric ALGS CVM Biotechnology median
Revenue growth (TTM) 893.01% 20.75% 5.64%
EPS growth (last fiscal year) 88.30% 59.06% —
Revenue growth, 5-year CAGR — 16.18% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALGS CVM Biotechnology median
Debt to equity 0.00 0.35 0.00
Current ratio 2.19 1.48 4.73
Net debt to EBITDA 0.87 0.25 0.96

Dividend

Metric ALGS CVM Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ALGS CVM Biotechnology median
Market cap 32.60m 30.25m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack